TY - JOUR
T1 - Pharmacologic therapy for type 2 diabetes
T2 - Synopsis of the 2017 American diabetes association standards of medical care in diabetes
AU - Chamberlain, James J.
AU - Herman, William H.
AU - Leal, Sandra
AU - Rhinehart, Andrew S.
AU - Shubrook, Jay H.
AU - Skolnik, Neil
AU - Kalyani, Rita Rastogi
N1 - Publisher Copyright:
© 2017 American College of Physicians.
PY - 2017/4/18
Y1 - 2017/4/18
N2 - Description: The American Diabetes Association (ADA) annually updates the Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes. Methods: For the 2017 Standards, the ADA Professional Practice Committee updated previous MEDLINE searches performed from 1 January 2016 to November 2016 to add, clarify, or revise recommendations based on new evidence. The committee rates the recommendations as A, B, or C, depending on the quality of evidence, or E for expert consensus or clinical experience. The Standards were reviewed and approved by the Executive Committee of the ADA Board of Directors, which includes health care professionals, scientists, and laypersons. Feedback from the larger clinical community informed revisions. Recommendations: This synopsis focuses on recommendations from the 2017 Standards about pharmacologic approaches to glycemic treatment of type 2 diabetes.
AB - Description: The American Diabetes Association (ADA) annually updates the Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes. Methods: For the 2017 Standards, the ADA Professional Practice Committee updated previous MEDLINE searches performed from 1 January 2016 to November 2016 to add, clarify, or revise recommendations based on new evidence. The committee rates the recommendations as A, B, or C, depending on the quality of evidence, or E for expert consensus or clinical experience. The Standards were reviewed and approved by the Executive Committee of the ADA Board of Directors, which includes health care professionals, scientists, and laypersons. Feedback from the larger clinical community informed revisions. Recommendations: This synopsis focuses on recommendations from the 2017 Standards about pharmacologic approaches to glycemic treatment of type 2 diabetes.
UR - http://www.scopus.com/inward/record.url?scp=85021389331&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021389331&partnerID=8YFLogxK
U2 - 10.7326/M16-2937
DO - 10.7326/M16-2937
M3 - Article
C2 - 28288484
AN - SCOPUS:85021389331
SN - 0003-4819
VL - 166
SP - 572
EP - 578
JO - Annals of internal medicine
JF - Annals of internal medicine
IS - 8
ER -